Strong clinical efficacy data from Phase 1 Cohort C with 11 of 14 patients achieving complete donor chimerism, 93% response rate, good safety profile, ahead-of-schedule enrollment, and successful commercial-ready manufacturing process. Company advancing to pivotal Phase 3 trial as planned, indicating progress toward commercialization.
Company is advancing its lead program TSC-101 toward pivotal Phase 3 trial with strong physician support and robust enrollment in Cohort C. Expanding pipeline with two additional candidates (TSC-102-A01 and TSC-102-A03) that could double addressable patient population. Improved financial performance with lower net loss ($28.7M vs $34.1M YoY) and adequate cash runway into H2 2027. Multiple near-term catalysts planned for 2026.
The company achieved multiple positive milestones including completion of Cohort C enrollment in its lead Phase 1 trial, FDA clearance for two IND applications, and advancement to commercial-ready manufacturing processes. These represent meaningful progress in clinical development and regulatory pathway advancement.
Company achieved multiple positive milestones including completion of Cohort C enrollment with commercial-ready manufacturing process, FDA clearance for two new IND applications expanding HLA coverage, and plans for pivotal trial launch. These developments represent significant clinical and regulatory progress that nearly double the addressable patient population in their heme program.
Articles that tag TCRX but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
